Zhenbo Hu
YOU?
Author Swipe
View article: Mesenchymal Stem Cell-Derived Exosomes Can Effectively Improve the Hair Count and Terminal Hair Diameter in Androgenetic Alopecia
Mesenchymal Stem Cell-Derived Exosomes Can Effectively Improve the Hair Count and Terminal Hair Diameter in Androgenetic Alopecia Open
Background and Objective: Androgenetic alopecia (AGA) is a common cause of male hair loss, and it is urgent to explore effective treatments. The purpose of this study was to evaluate the safety and preliminary efficacy of local injection o…
View article: Mesenchymal Stem Cell Exosomes Therapy for Acquired Trichorrhexis Nodosa: A Case Series
Mesenchymal Stem Cell Exosomes Therapy for Acquired Trichorrhexis Nodosa: A Case Series Open
Background Recent preclinical studies have demonstrated the potential efficacy of stem cell exosomes in the treatment of hair loss. However, there is a paucity of clinical studies investigating the application of exosomes for this purpose.…
View article: Dihydroartemisinin induces ferroptosis in T cell acute lymphoblastic leukemia cells by downregulating SLC7A11 and activating the ATF4‑CHOP signaling pathway
Dihydroartemisinin induces ferroptosis in T cell acute lymphoblastic leukemia cells by downregulating SLC7A11 and activating the ATF4‑CHOP signaling pathway Open
The present study aimed to investigate the anti-leukemic effects of dihydroartemisinin (DHA) on T-cell acute lymphoblastic leukemia (T-ALL) cell lines, Jurkat and Molt-4, and the underlying mechanisms. Cell Counting Kit-8 was performed to …
View article: Histone lysine demethylase 3B regulates autophagy via transcriptional regulation of <i>GABARAPL1</i> in acute myeloid leukemia cells
Histone lysine demethylase 3B regulates autophagy via transcriptional regulation of <i>GABARAPL1</i> in acute myeloid leukemia cells Open
Macroautophagy (hereafter referred to as autophagy) is a highly conserved self‑digestion process that is critical for maintaining homeostasis in response to various stresses. The autophagy‑related protein family, including the GABA type A …
View article: Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Table 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Table 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Table 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Data from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Data from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease control but not cure, necessitating continued investigation into alternative mechanistic approaches. Drugs that inhibit chromatin-modifying enzymes in…
View article: Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure 2 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Table 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Table 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Table 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Figure Legends 1-3, Table Legend from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure Legends 1-3, Table Legend from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure Legends 1-3, Table Legend from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure 3 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Figure 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Data from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Data from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Current drug therapy for metastatic renal cell cancer (RCC) results in temporary disease control but not cure, necessitating continued investigation into alternative mechanistic approaches. Drugs that inhibit chromatin-modifying enzymes in…
View article: Supplementary Figure Legends 1-3, Table Legend from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure Legends 1-3, Table Legend from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure Legends 1-3, Table Legend from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Supplementary Figure 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
Supplementary Figure 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer Open
Supplementary Figure 1 from Noncytotoxic Differentiation Treatment of Renal Cell Cancer
View article: Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A
Differentiation of imatinib -resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by Jiyuan Oridonin A Open
Chronic myeloid leukemia (CML) results from BCR-ABL oncogene, which blocks CML cells differentiation and protects these cells from apoptosis. T315I mutated BCR-ABL is the main cause of the resistance mediated by imatinib and second generat…
View article: JMJD1C Regulates Megakaryopoiesis in In Vitro Models through the Actin Network
JMJD1C Regulates Megakaryopoiesis in In Vitro Models through the Actin Network Open
The histone demethylase JMJD1C is associated with human platelet counts. The JMJD1C knockout in zebrafish and mice leads to the ablation of megakaryocyte–erythroid lineage anemia. However, the specific expression, function, and mechanism o…
View article: FOXK2 transcription factor and its roles in tumorigenesis (Review)
FOXK2 transcription factor and its roles in tumorigenesis (Review) Open
Forkhead box K2 (FOXK2) is a central transcriptional regulator of embryonic development and cell homeostasis. Since its discovery, evidence has shown that FOXK2 mediates a variety of biological processes involving in genomic stability, DNA…
View article: Exploring the oncogenic roles of LINC00857 in pan-cancer
Exploring the oncogenic roles of LINC00857 in pan-cancer Open
Although aberrant LINC00857 expression may play a key role in oncogenesis, no research has analyzed the pan-cancer oncogenic roles of LINC00857, particularly in tumor immunology. Here, we integrated data from several databases to analyze t…
View article: Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells
Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells Open
Acute myeloid leukemia (AML) is an aggressive form of hematological neoplasia characterized by failure of myeloid differentiation. AML is a leading cause of death from leukemia. Cytarabine chemotherapy resistance is a major source of refra…
View article: Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells
Histone Deacetylase Inhibitor I3 Induces the Differentiation of Acute Myeloid Leukemia Cells with t (8; 21) or MLL Gene Translocation and Leukemic Stem-Like Cells Open
Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by the clonal expansion and differentiation arrest of leukemic cells in peripheral blood and bone marrow. Though the treatment using cytarabine-based protocol for AML p…
View article: Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride
Lysophosphatidic acid protects cervical cancer HeLa cells from apoptosis induced by doxorubicin hydrochloride Open
Cervical cancer is one of the most common types of gynecological tumors. Lysophosphatidic acid (LPA), as a bioactive lipid medium, plays an important role in numerous physiological and pathophysiological processes, including the stimulatio…
View article: Honokiol Induces Ferroptosis by Upregulating HMOX1 in Acute Myeloid Leukemia Cells
Honokiol Induces Ferroptosis by Upregulating HMOX1 in Acute Myeloid Leukemia Cells Open
Acute myeloid leukemia (AML) is one of the malignant hematological cancers with high mortality. Finding a more effective and readily available treatment is of the utmost importance. Here, we aimed to identify the anti-leukemia effect of a …
View article: The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification
The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements via Epigenetic Modification Open
Acute leukemia (AL) is characterized by excessive proliferation and impaired differentiation of leukemic cells. AL includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Previous studies have demonstrated that about …
View article: The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells
The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells Open
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by reduced differentiation of myeloid cells and uncontrolled cell proliferation. AML is prone to drug resistance and has a high recurrence rate during tre…
View article: KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells Open
The lysine demethylase KDM2A (also known as JHDM1A or FBXL11) demethylates histone H3 at lysine K36 which lead to epigenetic regulation of cell proliferation and tumorigenesis. However, many biological processes are mediated by KDM2A indep…
View article: Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways
Jiyuan Oridonin A Overcomes Differentiation Blockade in Acute Myeloid Leukemia Cells With MLL Rearrangements via Multiple Signaling Pathways Open
Differentiation therapy with all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), has been extremely successful in inducing clinical remission in APL patients. However, the differ…